Regulatory Perspectives on RWE: Implications for Drug Approvals
The integration of Real-World Evidence (RWE) into healthcare decision-making is transforming the landscape of pharmaceutical development, pricing, and reimbursement strategies in the United States. To explore these advancements, the EVIDENCE 360: RWE, Pricing & Reimbursement Summit USA is scheduled for June 26-27, 2025, in Philadelphia.
Summit Overview
This two-day event aims to unite healthcare professionals, pharmaceutical leaders, policymakers, researchers, and data scientists to discuss the pivotal role of Real World Evidence in shaping healthcare policies and market access strategies. The summit will focus on innovative approaches to leveraging Real World Evidence to enhance patient outcomes and optimize healthcare costs.
Key Topics
The summit will address several critical areas:
Bridging Clinical Trials and Real-World Outcomes: Strategies to improve healthcare access by aligning clinical trial data with real-world patient experiences.
Advancements in Data Analytics: Utilizing AI, machine learning, and big data to extract actionable insights from real-world datasets.
Patient-Centric Data Utilization: Incorporating Patient-Reported Outcomes (PROs) to drive patient-centered care and inform access strategies.
Navigating U.S. Reimbursement Policies: Addressing the complexities of fragmented reimbursement frameworks within the U.S. healthcare system.
Health Technology Assessments (HTAs): Exploring the differences between U.S. HTA practices and global approaches to align pricing and reimbursement strategies with evolving healthcare policies.
Why Attend?
Attendees will gain valuable insights into:
The latest RWE trends and their influence on pricing and reimbursement strategies in the U.S.
The role of RWE in regulatory decision-making and its impact on HTAs.
The integration of AI and digital health in driving efficient reimbursement decisions.
Collaborative approaches to overcoming challenges in RWE integration and enhancing patient outcomes.
Target Audience
The summit is designed for:
Pharmaceutical and Biotech Executives: Involved in drug development, market access, and pricing strategies.
Regulators and Policymakers: From healthcare authorities and HTA agencies across the U.S.
Researchers: Specializing in RWE to assess treatment outcomes and support regulatory submissions.
Advisors and Payers: Providing guidance on pricing strategies, reimbursement, and RWE implementation.
Investors: Interested in funding healthcare innovations, particularly in RWE and value-based pricing models.
Notable Speakers
The summit will feature industry experts such as:
Sunil Dravida: Global Head, Real World Data, Takeda.
Pamela Landsman-Blumberg: Senior Vice President of Real-World Evidence & HEOR Strategy, Magnolia Market Access.
Lin Wang: Director, Global HEOR, Cell Therapy, Bristol Myers Squibb.
Charles Makin: Head, RWE, Boehringer Ingelheim.
Ravi Iyer: Senior Director, Head Real World Evidence Strategy, Global HEOR, Teva Pharmaceuticals.
These speakers will share their insights on leveraging RWE for drug pricing and reimbursement, aligning with the themes of the RWE Pricing & Reimbursement Summit USA.
For more information and to register for the summit at
https://veridonglobal.com/events/evidence-360-rwe-pricing-reimbursement-summit-usa/evidance-360-usa-registration/
Participating in this summit will provide attendees with the knowledge and connections necessary to navigate the evolving landscape of RWE and its application in pharmaceutical pricing and reimbursement strategies in the U.S.
Regulatory Perspectives on RWE: Implications for Drug Approvals
The integration of Real-World Evidence (RWE) into healthcare decision-making is transforming the landscape of pharmaceutical development, pricing, and reimbursement strategies in the United States. To explore these advancements, the EVIDENCE 360: RWE, Pricing & Reimbursement Summit USA is scheduled for June 26-27, 2025, in Philadelphia.
Summit Overview
This two-day event aims to unite healthcare professionals, pharmaceutical leaders, policymakers, researchers, and data scientists to discuss the pivotal role of Real World Evidence in shaping healthcare policies and market access strategies. The summit will focus on innovative approaches to leveraging Real World Evidence to enhance patient outcomes and optimize healthcare costs.
Key Topics
The summit will address several critical areas:
Bridging Clinical Trials and Real-World Outcomes: Strategies to improve healthcare access by aligning clinical trial data with real-world patient experiences.
Advancements in Data Analytics: Utilizing AI, machine learning, and big data to extract actionable insights from real-world datasets.
Patient-Centric Data Utilization: Incorporating Patient-Reported Outcomes (PROs) to drive patient-centered care and inform access strategies.
Navigating U.S. Reimbursement Policies: Addressing the complexities of fragmented reimbursement frameworks within the U.S. healthcare system.
Health Technology Assessments (HTAs): Exploring the differences between U.S. HTA practices and global approaches to align pricing and reimbursement strategies with evolving healthcare policies.
Why Attend?
Attendees will gain valuable insights into:
The latest RWE trends and their influence on pricing and reimbursement strategies in the U.S.
The role of RWE in regulatory decision-making and its impact on HTAs.
The integration of AI and digital health in driving efficient reimbursement decisions.
Collaborative approaches to overcoming challenges in RWE integration and enhancing patient outcomes.
Target Audience
The summit is designed for:
Pharmaceutical and Biotech Executives: Involved in drug development, market access, and pricing strategies.
Regulators and Policymakers: From healthcare authorities and HTA agencies across the U.S.
Researchers: Specializing in RWE to assess treatment outcomes and support regulatory submissions.
Advisors and Payers: Providing guidance on pricing strategies, reimbursement, and RWE implementation.
Investors: Interested in funding healthcare innovations, particularly in RWE and value-based pricing models.
Notable Speakers
The summit will feature industry experts such as:
Sunil Dravida: Global Head, Real World Data, Takeda.
Pamela Landsman-Blumberg: Senior Vice President of Real-World Evidence & HEOR Strategy, Magnolia Market Access.
Lin Wang: Director, Global HEOR, Cell Therapy, Bristol Myers Squibb.
Charles Makin: Head, RWE, Boehringer Ingelheim.
Ravi Iyer: Senior Director, Head Real World Evidence Strategy, Global HEOR, Teva Pharmaceuticals.
These speakers will share their insights on leveraging RWE for drug pricing and reimbursement, aligning with the themes of the RWE Pricing & Reimbursement Summit USA.
For more information and to register for the summit at https://veridonglobal.com/events/evidence-360-rwe-pricing-reimbursement-summit-usa/evidance-360-usa-registration/
Participating in this summit will provide attendees with the knowledge and connections necessary to navigate the evolving landscape of RWE and its application in pharmaceutical pricing and reimbursement strategies in the U.S.
